Desmond Schatz, United States of America

University of Florida Pediatrics
Desmond Schatz, MD is Professor and Interim Chair of Pediatrics, Medical Director of the Diabetes Institute and Director of the Clinical Research Center within the CTSI at the University of Florida, Gainesville. He served as President of Science and Medicine of the American Diabetes Association in 2016. Dr. Schatz has been involved in Type 1 diabetes research since the mid 1980’s and has published over 360 manuscripts, the majority related to the prediction, natural history, genetics, immunopathogenesis and prevention of the disease, as well as the management of children and adolescents with Type 1 diabetes. He is the Principal Investigator (PI) on several NIH awards. He is the PI of the University of Florida Clinical Center participating in the NIH-funded TrialNet (a founding member of the DPT-1 in 1994). He is co-PI on a Program Project Grant seeking to understand the immunopathogenesis of Type 1 diabetes, and also serve as PI for the NIH-funded international newborn genetic screening (TEDDY) program in North Central Florida. He is the PI on the NIH-funded Human Islet Research Network (HIRN) Grant evaluating novel markers and mechanisms of beta cell destruction. He is the PI of the University of Florida site participating in the Type 1 Diabetes Exchange. Dr. Schatz has served in numerous capacities (Committees, Study Sections) for the American Diabetes Association, JDRF and NIH. He serves on the external advisory board for the NIH- and CDC-funded SEARCH and TODAY studies in youth with Type 2 diabetes and on the JDRF-funded Australian INIT II studies. He was awarded the Mary Tyler Moore and S Robert Levine JDRF Excellence in Clinical Research Award, the 2009 Cure Award from the American Diabetes Association, the 2010 Public Policy Leadership Award, the prestigious Banting Medal for service from the American Diabetes Association and the ISPAD Prize for achievement (the highest honor of the International Society for Pediatric and Adolescent Diabetes)

Presenter of 2 Presentations

Efficacy of low dose antithymocyte globulin in new-onset type 1 diabetes: Implication for prevention

Session Type
PARALLEL SESSION
Date
20.02.2020, Thursday
Session Time
13:00 - 14:30
Channel
La Paz
Lecture Time
13:40 - 14:00

Abstract

Background and Aims / Part 1

Several immunotherapies (including rituximab, abatacept, teplizumab, alefacept, high-dose anti-thymocyte globulin (ATG), and low-dose ATG±G-CSF) have demonstrated transient endogenous insulin preservation in recent-onset type 1 diabetes. Study sought to determine two year outcome of new onset type 1 patients treated with ATG±G-CSF compared to placebo. Futher anaylases were undertaken to determine most efficaceous therapy.

Methods / Part 2

1. Double blind plecebo controlled study 2. C-peptide 2 hour area under curve means modeled using ANCOVA

Results / Part 3

Low -dose anti-thymocyte globulin (ATG, 2.5mg/kg) has been shown to preserve β cell function for now at least 2 years following the onset of type 1 diabetes (T1D) as well as improving HbA1c. Immunological studies suggest a depletion in conventional CD4 T cells whilst preserving regulatory T cells. Preliminary studies suggest that of the `successful’ studies performed to date, low-dose ATG demonstrates the greatest C-peptide preservation.

Conclusions / Part 4

Future studies are being planned to determine whether low-dose ATG might prevent or delay the onset of type 1 diabetes.

Hide

Immune intervention for type 1 diabetes

Session Type
PLENARY SESSION
Date
21.02.2020, Friday
Session Time
13:00 - 14:30
Channel
Auditorium A
Lecture Time
14:06 - 14:13